Chief Operating Officer - Helen Delahaye
Helen has extensive strategic and technical knowledge of the drug development process spanning over 20 years and covering research, development and commercialisation. She provides interim management to a number of blue-chip biopharma clients via her consultancy, Deltohn Ltd with the aim to assist companies to improve efficiency, productivity and profitability. Prior to this, Helen has held senior management positions at Quintiles, Huntingdon Life Sciences and ProStrakan. Helen manages the day to day operations of the company and shepherd the clinical program through Phase I/IIa development.
Chief Scientific Officer and Director - Anthony Hollander
Anthony is a World leading scientist who pioneered the first tissue engineered trachea transplant to critical acclaim before founding Azellon. In 2010, the "Times" newspaper ranking of Britain's 100 most important scientists included him at number 39 on the list. He is President-elect of the International Cartilage Repair Society. Anthony is responsible for all scientific activities in the company and is also Head of the School of Cell Biology and Molecular Medicine at the University of Bristol.